Page 227 - Haematologica - Vol. 105 n. 6 - June 2020

FHL2 modulates thrombosis formation
References
1. RaskobGE,AngchaisuksiriP,BlancoAN.,et al. Thrombosis: a major contributor to the global disease burden. J Thromb Haemost. 2014;12(10):1580-1590.
2. Aras O, Shet A, Bach RR, et al. Induction of microparticle- and cell-associated intravas- cular tissue factor in human endotoxemia. Blood. 2004;103(12):4545-4553.
3. Cimmino G, Ciccarelli G, Golino P. Role of tissue factor in the coagulation network. Semin Thromb Hemost. 2015;41(7):708- 717.
4. Kakkar AK, DeRuvo N, Chinswangwatanakul V, Tebbutt S, Williamson RC. Extrinsic-pathway activa- tion in cancer with high factor VIIa and tis- sue factor. Lancet. 1995;346(8981):1004- 1005.
5. Lijfering WM, Rosendaal FR, Cannegieter SC. Risk factors for venous thrombosis - cur- rent understanding from an epidemiological point of view. Br J Haematol. 2010;149(6): 824-833.
6. Rosendaal FR. Venous thrombosis: a multi- causal disease. Lancet. 1999;353(9159):1167- 1173.
7. Drake TA, Cheng J, Chang A, Taylor FB, Jr. Expression of tissue factor, thrombomod- ulin, and E-selectin in baboons with lethal Escherichia coli sepsis. Am J Pathol. 1993;142(5):1458-1470.
8. Lupu C, Westmuckett AD, Peer G, et al. Tissue factor-dependent coagulation is pref- erentially up-regulated within arterial branching areas in a baboon model of Escherichia coli sepsis. Am J Pathol. 2005;167(4):1161-1172.
9. Song D, Ye X, Xu H, Liu SF. Activation of endothelial intrinsic NF-{kappa}B pathway impairs protein C anticoagulation mecha- nism and promotes coagulation in endotox- emic mice. Blood. 2009;114(12):2521-2529.
10. Pawlinski R, Mackman N. Cellular sources of tissue factor in endotoxemia and sepsis. Thromb Res. 2010;125 Suppl 1:S70-S73.
11. Posma JJ, Posthuma JJ, Spronk HM. Coagulation and non-coagulation effects of thrombin. J Thromb Haemost. 2016;14(10):1908-1916.
12. Breitenstein A, Tanner FC, Luscher TF. Tissue factor and cardiovascular disease: quo vadis? Circ J. 2010;74(1):3-12.
13. Gertz SD, Fallon JT, Gallo R, et al. Hirudin reduces tissue factor expression in neointi- ma after balloon injury in rabbit femoral and porcine coronary arteries. Circulation. 1998;98(6):580-587.
14. Moons AH, Levi M, Peters RJ. Tissue factor and coronary artery disease. Cardiovasc Res. 2002;53(2):313-325.
15. Speidel CM, Eisenberg PR, Ruf W, Edgington TS, Abendschein DR. Tissue fac- tor mediates prolonged procoagulant activi- ty on the luminal surface of balloon-injured aortas in rabbits. Circulation. 1995;92(11): 3323-3330.
16. van der Wal AC, Li X, de Boer OJ. Tissue factor expression in the morphologic spec- trum of vulnerable atherosclerotic plaques. Semin Thromb Hemost. 2006;32(1):40-47.
17. Lopez-Pedrera C, Buendia P, Barbarroja N, Siendones E, Velasco F, Cuadrado MJ. Antiphospholipid-mediated thrombosis: interplay between anticardiolipin antibodies and vascular cells. Clin Appl Thromb Hemost. 2006;12(1):41-45.
18. Khechai F, Ollivier V, Bridey F, Amar M,
Hakim J, de Prost D. Effect of advanced gly- cation end product-modified albumin on tis- sue factor expression by monocytes. Role of oxidant stress and protein tyrosine kinase activation. Arterioscler Thromb Vasc Biol. 1997;17(11):2885-2890.
19. Reverter JC, Tassies D, Font J, et al. Hypercoagulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free protein s. Arterioscler Thromb Vasc Biol. 1996; 16(11):1319-1326.
20. Solovey A, Gui L, Key NS, Hebbel RP. Tissue factor expression by endothelial cells in sick- le cell anemia. J Clin Invest. 1998;101 (9):1899-1904.
21. Osterud B, Bjorklid E. Sources of tissue fac- tor. Semin Thromb Hemost. 2006;32(1):11- 23.
22. Colucci M, Balconi G, Lorenzet R, et al. Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest. 1983;71(6):1893-1896.
23. Nawroth PP, Handley DA, Esmon CT, Stern DM. Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci U S A. 1986;83(10):3460-3464.
24. Scarpati EM, Sadler JE. Regulation of endothelial cell coagulant properties. Modulation of tissue factor, plasminogen activator inhibitors, and thrombomodulin by phorbol 12-myristate 13-acetate and tumor necrosis factor. J Biol Chem. 1989;264(34):20705-20713.
25. Mackman N. Regulation of the tissue factor gene. FASEB J. 1995;9(10):883-889.
26. Mackman N, Morrissey JH, Fowler B, Edgington TS. Complete sequence of the human tissue factor gene, a highly regulated cellular receptor that initiates the coagula- tion protease cascade. Biochemistry. 1989;28(4):1755-1762.
27. Johannessen M, Moller S, Hansen T, Moens U, Van GM. The multifunctional roles of the four-and-a-half-LIM only protein FHL2. Cell Mol Life Sci. 2006;63(3):268-284.
28. Kurakula K, Sommer D, Sokolovic M, et al. LIM-only protein FHL2 is a positive regula- tor of liver X receptors in smooth muscle cells involved in lipid homeostasis. Mol Cell Biol. 2015;35(1):52-62.
29. Kurakula K, van der Wal E, Geerts D, van Tiel CM, de Vries CJ. FHL2 protein is a novel co-repressor of nuclear receptor Nur77. J Biol Chem. 2011;286(52):44336-44343.
30. Kurakula K, Vos M, Otermin Rubio I, et al. The LIM-only protein FHL2 reduces vascu- lar lesion formation involving inhibition of proliferation and migration of smooth mus- cle cells. PLoS One. 2014;9(4):e94931.
31. Tran MK, Kurakula K, Koenis DS, de Vries CJ. Protein-protein interactions of the LIM- only protein FHL2 and functional implica- tion of the interactions relevant in cardiovas- cular disease. Biochim Biophys Acta. 2016;1863(2):219-228.
32. Kuijpers MJ, de Witt S, Nergiz-Unal R, et al. Supporting roles of platelet throm- bospondin-1 and CD36 in thrombus forma- tion on collagen. Arterioscler Thromb Vasc Biol. 2014;34(6):1187-1192.
33. de Vries CJ, van Achterberg TA, Horrevoets AJ, ten Cate JW, Pannekoek H. Differential display identification of 40 genes with altered expression in activated human smooth muscle cells. Local expression in atherosclerotic lesions of smags, smooth muscle activation-specific genes. J Biol
Chem. 2000;275(31):23939-23947.
34. Kurakula K, Vos M, van Eijk M, Smits HH, de Vries CJ. LIM-only protein FHL2 regu- lates experimental pulmonary Schistosoma mansoni egg granuloma formation. Eur J
Immunol. 2015;45(11):3098-3106.
35. van den Hengel LG, Osanto S, Reitsma PH, Versteeg HH. Murine tissue factor coagulant activity is critically dependent on the pres- ence of an intact allosteric disulfide.
Haematologica. 2013;98(1):153-158.
36. Mackman N, Fowler BJ, Edgington TS, Morrissey JH. Functional analysis of the human tissue factor promoter and induction by serum. Proc Natl Acad Sci U S A.
1990;87(6):2254-2258.
37. Germain M, Chasman DI, de Haan H, et al.
Meta-analysis of 65,734 individuals identi- fies TSPAN15 and SLC44A2 as two suscep- tibility loci for venous thromboembolism. Am J Hum Genet. 2015;96(4):532-542.
38. van Hylckama Vlieg A, Baglin CA, Luddington R, MacDonald S, Rosendaal FR, Baglin TP. The risk of a first and a recurrent venous thrombosis associated with an elevated D-dimer level and an ele- vated thrombin potential: results of the THE-VTE study. J Thromb Haemost. 2015; 13(9):1642-1652.
39. Kuijpers MJ, Munnix IC, Cosemans JM, et al. Key role of platelet procoagulant activity in tissue factor-and collagen-dependent thrombus formation in arterioles and venules in vivo differential sensitivity to thrombin inhibition. Microcirculation. 2008;15(4):269-282.
40. Wang L, Miller C, Swarthout RF, Rao M, Mackman N, Taubman MB. Vascular smooth muscle-derived tissue factor is criti- cal for arterial thrombosis after ferric chlo- ride-induced injury. Blood. 2009;113(3):705- 713.
41. Martorell L, Martinez-Gonzalez J, Rodriguez C, Gentile M, Calvayrac O, Badimon L. Thrombin and protease-activat- ed receptors (PARs) in atherothrombosis. Thromb Haemost. 2008;99(2):305-315.
42. Oltrona L, Speidel CM, Recchia D, Wickline SA, Eisenberg PR, Abendschein DR. Inhibition of tissue factor-mediated coagula- tion markedly attenuates stenosis after bal- loon-induced arterial injury in minipigs. Circulation. 1997;96(2):646-652.
43. Guo Z, Zhang W, Xia G, et al. Sp1 upregu- lates the four and half lim 2 (FHL2) expres- sion in gastrointestinal cancers through tran- scription regulation. Mol Carcinog. 2010;49(9):826-836.
44. Dorfleutner A, Hintermann E, Tarui T, Takada Y, Ruf W. Cross-talk of integrin alpha3beta1 and tissue factor in cell migra- tion. Mol Biol Cell. 2004;15(10):4416-4425.
45. Wixler V, Geerts D, Laplantine E, et al. The LIM-only protein DRAL/FHL2 binds to the cytoplasmic domain of several alpha and beta integrin chains and is recruited to adhe- sion complexes. J Biol Chem. 2000;275(43): 33669-33678.
46. Xia T, Levy L, Levillayer F, et al. The four and a half LIM-only protein 2 (FHL2) activates transforming growth factor β (TGF-β) sig- naling by regulating ubiquitination of the E3 ligase Arkadia. J Biol Chem. 2013;288 (3):1785-1794.
47. Hayashi H, Nakagami H, Takami Y, et al. FHL-2 suppresses VEGF-induced phos- phatidylinositol 3-kinase/Akt activation via interaction with sphingosine kinase-1. Arterioscler Thromb Vasc Biol. 2009;29(6): 909-914.
haematologica | 2020; 105(6)
1685